Kezar Life Sciences Inc (NASDAQ:KZR) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $27.00 for the company and are anticipating that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given Kezar Life Sciences an industry rank of 112 out of 255 based on the ratings given to related companies.

Several equities research analysts have weighed in on the company. Wells Fargo & Co assumed coverage on Kezar Life Sciences in a report on Monday, July 16th. They issued an “outperform” rating and a $30.00 target price for the company. Jefferies Financial Group assumed coverage on Kezar Life Sciences in a report on Monday, July 16th. They issued a “buy” rating and a $23.00 target price for the company. Cowen assumed coverage on Kezar Life Sciences in a report on Monday, July 16th. They issued an “outperform” rating for the company. Finally, William Blair assumed coverage on Kezar Life Sciences in a report on Monday, July 16th. They issued an “outperform” rating for the company.

Kezar Life Sciences stock traded up $0.07 during mid-day trading on Tuesday, hitting $20.48. The company’s stock had a trading volume of 44,100 shares, compared to its average volume of 56,545. Kezar Life Sciences has a one year low of $14.77 and a one year high of $21.34.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Thursday, August 9th. The company reported ($3.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($2.77). equities analysts expect that Kezar Life Sciences will post -2.64 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the business. Laurion Capital Management LP purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $173,000. BlackRock Inc. purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $173,000. MYDA Advisors LLC purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $213,000. Dean Capital Investments Management LLC purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $585,000. Finally, Prosight Management LP purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter worth $721,000. Institutional investors and hedge funds own 42.18% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Featured Story: Terms to Better Understand Call Options

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.